Psoriasis News and Research

Latest Psoriasis News and Research

Ligand and GSK amend agreement to pursue independent research programs

Ligand Pharmaceuticals Incorporated today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline, GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would otherwise have been required upon the identification of a new lead chemical series for advancement in its alliance with GSK.

29 Sep 2009

Stelara approved by the FDA for treating psoriasis

The U.S. Food and Drug Administration today approved Stelara (ustekinumab), a biologic product for adults who have a moderate to severe form of psoriasis.

25 Sep 2009

$4.5 million cost involved for MLSIC set up

The Michigan Economic Development Corp. (MEDC), Ann Arbor SPARK, Greater Wayne Economic Development Corporation and a private foundation have collaborated to create the Michigan Life Science and Innovation Center (MLSIC). MLSIC will connect well-funded, experienced entrepreneurs with business accelerator organizations and start-up life science companies.

25 Sep 2009

Symposium on genetics of psoriasis and psoriatic arthritis to be held

A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the Kempinski Hotel Bristol - Salon Charlottenburg-Cecilienhof, Kurfürstendamm 27, D-10719, Berlin, Germany.

24 Sep 2009

NIHR to fund patient panel for skin disease research

People who suffer from skin disease are being asked to help make research more effective by joining a new 'Patient Panel'.

24 Sep 2009

LEO Pharma re-acquires product licensing rights from Warner Chilcott

Warner Chilcott plc (Nasdaq: WCRX) and LEO Pharma announced today that, in exchange for a one-time cash payment of $1.0 billion to Warner Chilcott, LEO Pharma is re-acquiring Warner Chilcott's exclusive product licensing rights in the United States to its topical psoriasis treatments Taclonex(R), Taclonex Scalp(R), Dovonex(R) as well as rights to all products in LEO's development pipeline, and acquiring all inventories of the products.

24 Sep 2009

Comprehensive and practical overview of psoriasis

Treatments for psoriasis often present a therapeutic challenge to physicians because, besides affecting the skin, psoriasis may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases).

22 Sep 2009

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.

21 Sep 2009

Clinical trial results of topical INCB18424 inhibitor announced by Incyte Corporation

Incyte Corporation (Nasdaq:INCY) announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis.

21 Sep 2009

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009

Nasdaq Stock Market issues noncompliance notice to PhotoMedex

PhotoMedex, Inc. (Nasdaq:PHMD) (the “Company”) announced today that it received notification from The Nasdaq Stock Market (“Nasdaq”) on September 15, 2009 that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq’s Global Market exchange under Nasdaq Marketplace Rule 4450(a)(5) (the “Rule”).

19 Sep 2009

Resolvyx Pharmaceuticals receives U.S. patent for RX-10045

Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.

19 Sep 2009

Updated financial information released by avVaa World Health

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced the release of updated financial information.

19 Sep 2009

PhotoMedex unveils Neova DNA Repair Factor Nourishing Lotion

PhotoMedex, Inc., a leading provider of advanced dermatology, clinical skincare and medical laser products, today announced Neova DNA Repair Factor Nourishing Lotion, the newest addition to its renowned Neova brand of skin and hair products.

16 Sep 2009

PsoriasisDX Genetic Test for Psoriatic arthritis launched

The first genetic test for Psoriatic arthritis (PsA) is being launched today by PsoriasisDX, LLC, a subsidiary of molecular dermatology research and development innovator PharmaGenoma, Inc. PsA is a progressive irreversible joint disease associated with psoriasis. It is estimated that 20% to 40% of psoriasis patients will eventually develop PsA.

16 Sep 2009

Neuroskin Psoriasis Relief DRTV test results announced by avVaa World Health Care

15 Sep 2009

Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353

Biotie has started a clinical trial with its phosphodiesterase 4 (PDE4) inhibitor ELB353, having received the prerequisite regulatory and ethical clearances for the clinical trial application.

14 Sep 2009

Internet marketing program from AVVH

14 Sep 2009

Quatrx' second phase 3 study of ospemifene tablets provides positive results

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).

10 Sep 2009

BioTrends Research Group ranked by Philadelphia 100 for the second consecutive time

For the second year in a row, BioTrends Research Group, Inc. has been ranked as one of the fastest-growing, privately-held companies in the Philadelphia region by the Philadelphia 100, a joint project of the Wharton Small Business Development Center, the Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal.

10 Sep 2009